{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T05:05:55Z","timestamp":1784696755358,"version":"3.55.0"},"reference-count":22,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T00:00:00Z","timestamp":1784678400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Transthyretin (TTR) p.Ala45Thr variant is pathogenic, typically associated with cardiomyopathy and peripheral neuropathy. Leptomeningeal and central nervous system (CNS) involvement is rare, and longitudinal treatment data remain limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We conducted a single-patient longitudinal observational study of a patient with genetically confirmed hereditary transthyretin amyloidosis (ATTRv) carrying the\n                      <jats:italic>TTR<\/jats:italic>\n                      p.Ala45Thr variant with CNS involvement. The patient was followed over 5\u202fyears using multimodal assessments, including neurological and cognitive testing, cerebrospinal fluid (CSF) analysis, magnetic resonance imaging (MRI), and electrophysiological studies.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A 48-year-old woman presented with progressive neurological symptoms beginning at age 37, including gait ataxia, dysarthria, and left hypoesthesia. Family history was notable for early-onset neurological decline in maternal relatives. Baseline MRI showed cerebellar micro-hemorrhages, leptomeningeal enhancement, and a cervical spinal cord lesion (C4\u2013C7). CSF protein was markedly elevated, and genetic testing confirmed the TTR p.Ala45Thr variant. Cardiac and peripheral nerve evaluations were unremarkable. Tolcapone therapy was initiated and titrated to the maximal dose. Over 5\u202fyears, follow-up assessments demonstrated progressive neurological and cognitive decline, increased CSF protein levels, and enlargement of the spinal cord lesion, with mild progression of leptomeningeal and ependymal enhancement on MRI.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This report highlights progressive CNS involvement in Ala45Thr-associated ATTR despite treatment with a CNS-penetrant TTR stabilizer. These findings suggest that disease progression may continue despite TTR stabilization in some patients and underscore the need for early intervention, systematic CNS monitoring, and further development of CNS-targeted therapies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2026.1853003","type":"journal-article","created":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T04:40:02Z","timestamp":1784695202000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Case Report: Five-year follow-up of leptomeningeal transthyretin amyloidosis (Ala45Thr) with CNS involvement under tolcapone therapy"],"prefix":"10.3389","volume":"13","author":[{"given":"Nata\u0161a","family":"Giedraitien\u0117","sequence":"first","affiliation":[{"name":"Faculty of Medicine, Clinic of Neurology and Neurosurgery, Institute of Clinical Medicine, Vilnius University","place":["Vilnius, Lithuania"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Egl\u0117","family":"Preik\u0161aitien\u0117","sequence":"additional","affiliation":[{"name":"Department of Human and Medical Genetics, Faculty of Medicine, Institute of Biomedical Sciences, Vilnius University","place":["Vilnius, Lithuania"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Au\u0161ra","family":"Klima\u0161auskien\u0117","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Clinic of Neurology and Neurosurgery, Institute of Clinical Medicine, Vilnius University","place":["Vilnius, Lithuania"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,22]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1080\/13506120600551814","article-title":"A case of biopsy-proven leptomeningeal amyloidosis and intravenous Ig-responsive polyneuropathy associated with the Ala25Thr transthyretin gene mutation","volume":"13","author":"Shimizu","year":"2006","journal-title":"Amyloid"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1002\/mus.10452","article-title":"Contribution of wild-type transthyretin to hereditary peripheral nerve amyloid","volume":"28","author":"Yazaki","year":"2003","journal-title":"Muscle Nerve"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"237","DOI":"10.3390\/medicina60020237","article-title":"Rare c.302C>T TTR variant associated with transthyretin amyloidosis","volume":"60","author":"\u017debrauskien\u0117","year":"2024","journal-title":"Medicina (Kaunas)"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1080\/10408363.2024.2350379","article-title":"Transthyretin mutagenesis: impact on amyloidogenesis and disease","volume":"61","author":"Almeida","year":"2024","journal-title":"Crit Rev Clin Lab Sci"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.jmb.2011.12.060","article-title":"The transthyretin amyloidoses: from delineating the molecular mechanism of aggregation linked to pathology to a regulatory-agency-approved drug","volume":"421","author":"Johnson","year":"2012","journal-title":"J Mol Biol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"e2036","DOI":"10.1212\/WNL.0000000000207158","article-title":"Phenotypes associated with the Val122Ile, Leu58His, and late-onset Val30Met variants in patients with hereditary transthyretin amyloidosis","volume":"100","author":"Zampino","year":"2023","journal-title":"Neurology"},{"key":"ref7","volume-title":"GeneReviews\u00ae [Internet]","author":"Sekijima","year":"1993"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"11070","DOI":"10.1021\/bi201365r","article-title":"Dissecting the structure, thermodynamic stability, and aggregation properties of the A25T transthyretin (A25T-TTR) variant involved in leptomeningeal amyloidosis: identifying protein partners that co-aggregate during A25T-TTR fibrillogenesis in cerebrospinal fluid","volume":"50","author":"Azevedo","year":"2011","journal-title":"Biochemistry"},{"key":"ref9","year":"2019"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1080\/13506129.2022.2056011","article-title":"CSF\/plasma levels, transthyretin stabilisation and safety of multiple doses of tolcapone in subjects with hereditary ATTR amyloidosis","volume":"29","author":"Takahashi","year":"2022","journal-title":"Amyloid"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1111\/febs.15339","article-title":"Tolcapone, a potent aggregation inhibitor for the treatment of familial leptomeningeal amyloidosis","volume":"288","author":"Pinheiro","year":"2021","journal-title":"FEBS J"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"115837","DOI":"10.1016\/j.ejmech.2023.115837","article-title":"PITB: a high affinity transthyretin aggregation inhibitor with optimal pharmacokinetic properties","volume":"261","author":"Pinheiro","year":"2023","journal-title":"Eur J Med Chem"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"14673","DOI":"10.1021\/acs.jmedchem","article-title":"Development of a highly potent transthyretin amyloidogenesis inhibitor: design, synthesis, and evaluation","volume":"65","author":"Pinheiro","year":"2022","journal-title":"J Med Chem"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"10787","DOI":"10.1038\/ncomms10787","article-title":"Repositioning tolcapone as a potent inhibitor of transthyretin amyloidogenesis and associated cellular toxicity","volume":"7","author":"Sant\u2019Anna","year":"2016","journal-title":"Nat Commun"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1080\/13506129.2020.1808783","article-title":"Blinded potency comparison of transthyretin kinetic stabilisers by subunit exchange in human plasma","volume":"28","author":"Nelson","year":"2021","journal-title":"Amyloid"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1080\/13506129.2019.1597702","article-title":"Transthyretin stabilization activity of the catechol- O-methyltransferase inhibitor tolcapone (SOM0226) in hereditary ATTR amyloidosis patients and asymptomatic carriers: proof-of-concept study","volume":"26","author":"Gamez","year":"2019","journal-title":"Amyloid"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1186\/s12887-025-06194-3","article-title":"A novel missense variant at the site of interaction between RLIM and E2 ubiquitin-conjugating enzymes causes T\u00f8nne-Kalscheuer syndrome","volume":"25","author":"Siavrien\u0117","year":"2025","journal-title":"BMC Pediatr"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1097\/01.lab.0000059937.11023.1f","article-title":"Energetic characteristics of the new transthyretin variant A25T may explain its atypical central nervous system pathology","volume":"83","author":"Sekijima","year":"2003","journal-title":"Lab Investig"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1080\/13506129.2022.2128331","article-title":"Distribution and progression of cerebral amyloid angiopathy in early-onset V30M (p.V50M) hereditary ATTR amyloidosis","volume":"30","author":"Takahashi","year":"2023","journal-title":"Amyloid"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/s00401-022-02501-9","article-title":"Neuropathology of central nervous system involvement in TTR amyloidosis","volume":"145","author":"Taipa","year":"2023","journal-title":"Acta Neuropathol"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"oeaf147","DOI":"10.1093\/ehjopen\/oeaf147","article-title":"Relative efficacy of tafamidis, acoramidis, patisiran and vutrisiran in patients with transthyretin cardiac amyloidosis: a network meta-analysis","volume":"5","author":"Aimo","year":"2025","journal-title":"Eur Heart J Open"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/s41582-019-0210-4","article-title":"Hereditary transthyretin amyloidosis: a model of medical progress for a fatal disease","volume":"15","author":"Adams","year":"2019","journal-title":"Nat Rev Neurol"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1853003\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T04:40:10Z","timestamp":1784695210000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1853003\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,22]]},"references-count":22,"alternative-id":["10.3389\/fmed.2026.1853003"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1853003","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,22]]},"article-number":"1853003"}}